-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 30, reporters learned on the 29th that the innovative class 1.
1 new drug, Saivotinib, independently developed by Chinese experts for 5 years, was approved by the National Medical Products Administration for the treatment of what was previously known as the "world problem".
Related types of non-small cell lung cancer (NSCLC)
.
1 new drug, Saivotinib, independently developed by Chinese experts for 5 years, was approved by the National Medical Products Administration for the treatment of what was previously known as the "world problem".
Related types of non-small cell lung cancer (NSCLC)
.
It is reported that while "Sivotinib" was approved for listing in China, related clinical studies in many other countries in Europe and America are also in full swing
.
This means that Syvotinib not only fills the gap in this type of targeted drugs in China, but is also expected to become a lung cancer targeted innovative drug that represents China to the world
.
.
This means that Syvotinib not only fills the gap in this type of targeted drugs in China, but is also expected to become a lung cancer targeted innovative drug that represents China to the world
.
Professor Lu Shun, director of the Oncology Department ofShanghai Chest Hospital , told reporters that Saivotinib will bring long-term survival hope to patients with non-small cell lung cancer with skip mutations in MET exon 14
.
According to reports, the MET exon 14 skipping mutation is the driving gene for non-small cell lung cancer (NSCLC).
Patients with this type of lung cancer have rapid disease progression, poor prognosis, and postoperative tumor metastasis
.
Its treatment has always been in dilemma.
In the past, only traditional chemotherapy could be used, but the overall survival time of patients was only 8.
1 months, which is a worldwide problem
.
.
According to reports, the MET exon 14 skipping mutation is the driving gene for non-small cell lung cancer (NSCLC).
Patients with this type of lung cancer have rapid disease progression, poor prognosis, and postoperative tumor metastasis
.
Its treatment has always been in dilemma.
In the past, only traditional chemotherapy could be used, but the overall survival time of patients was only 8.
1 months, which is a worldwide problem
.
Professor Lu Shun introduced in an interview that as early as 2015, he noticed the intractable target of MET
.
November 2016 began, led by Lu Shun China conducted a multi-center clinical trial designed to assess "who Wolfowitz imatinib treatment-related types of non-small cell lung cancer patients with the efficacy and safety"
.
The clinical trial enrolled patients in 32 centers across the country.
The objective response rate was as high as 49.
2%, the progression-free survival period was 6.
8 months, and the longest survival time was more than 4 years
.
.
November 2016 began, led by Lu Shun China conducted a multi-center clinical trial designed to assess "who Wolfowitz imatinib treatment-related types of non-small cell lung cancer patients with the efficacy and safety"
.
The clinical trial enrolled patients in 32 centers across the country.
The objective response rate was as high as 49.
2%, the progression-free survival period was 6.
8 months, and the longest survival time was more than 4 years
.
Mr.
Shen, now 72 years old, is the first patient enrolled in the clinical study
.
In 2017, after Mr.
Shen was diagnosed, the doctor quickly gave him chemotherapy, but the effect was not satisfactory
.
At that time, Lu Shun led the "Sivotinib" related clinical research started.
After Mr.
Shen entered the clinical research, after only taking the medicine for one month, the metastasis was reduced to 2.
4 cm
.
After taking the medicine for more than 3 months, the metastasis was further reduced to 1.
8 cm
.
After taking the medicine for more than four years, the tumor has always maintained this size
.
Now, the old man’s condition is very stable, as long as he comes to the hospital for review regularly
.
Shen, now 72 years old, is the first patient enrolled in the clinical study
.
In 2017, after Mr.
Shen was diagnosed, the doctor quickly gave him chemotherapy, but the effect was not satisfactory
.
At that time, Lu Shun led the "Sivotinib" related clinical research started.
After Mr.
Shen entered the clinical research, after only taking the medicine for one month, the metastasis was reduced to 2.
4 cm
.
After taking the medicine for more than 3 months, the metastasis was further reduced to 1.
8 cm
.
After taking the medicine for more than four years, the tumor has always maintained this size
.
Now, the old man’s condition is very stable, as long as he comes to the hospital for review regularly
.
From a survival period of more than 8 months to more than 4 years now, Professor Lu Shun’s research results on "Sivotinib" have enabled relevant patients to receive more precise treatment and continue their lives
.
The research results were published in the top international academic journal "The Lancet·Respiratory Medicine"
.
.
The research results were published in the top international academic journal "The Lancet·Respiratory Medicine"
.
In an interview with reporters, Professor Lu Shun took the research and development of new lung cancer drugs as an example, and described the history of China's new drug research and development
.
The expert said that from 1999 to 2009, China actively participated in international multi-center clinical research and learned the thinking and methods of clinical trials
.
From 2009 to 2019, Chinese experts not only participated in international multi-center research, but also began to participate in the discussion of experimental plans
.
After 20 years of learning, from 2019 to the present, China's clinical research capabilities have been continuously strengthened, and it has begun to make a "strong tone" in the development of new lung cancer drugs
.
.
The expert said that from 1999 to 2009, China actively participated in international multi-center clinical research and learned the thinking and methods of clinical trials
.
From 2009 to 2019, Chinese experts not only participated in international multi-center research, but also began to participate in the discussion of experimental plans
.
After 20 years of learning, from 2019 to the present, China's clinical research capabilities have been continuously strengthened, and it has begun to make a "strong tone" in the development of new lung cancer drugs
.
It is understood that in recent years, the expert team of Shanghai Chest Hospital has aimed at the research of targeted drugs and immunological drugs for lung cancer, and has actively explored new combined treatment strategies and diagnosis and treatment models
.
From the extremely low 5-year survival rate in the past, lung cancer patients can now live for 10, 15 years or even longer.
Lung cancer has gradually entered the era of "chronic disease"
.
.
From the extremely low 5-year survival rate in the past, lung cancer patients can now live for 10, 15 years or even longer.
Lung cancer has gradually entered the era of "chronic disease"
.
At the same time that Syvotinib was approved, "Tilelizumab combined with chemotherapy for the treatment of non-squamous non-small cell lung cancer" and "Atelizumab combined with chemotherapy for the treatment of non-squamous non-small cell lung cancer" were also approved
.
Professor Lu Shun is the main investigator of these two immunological drugs, bringing treatment options and survival benefits to more types of lung cancer patients
.
The latest research results show that tislelizumab performs well in the first-line treatment of non-squamous non-small cell lung cancer, can significantly prolong progression-free survival, and overall survival has a trend of benefit
.
Relevant research results suggest that atelizumab combined with chemotherapy has shown more significant efficacy and benefits in Asian populations, and more and more Chinese lung cancer patients will benefit from this immunotherapy
.
(Finish)
.
Professor Lu Shun is the main investigator of these two immunological drugs, bringing treatment options and survival benefits to more types of lung cancer patients
.
The latest research results show that tislelizumab performs well in the first-line treatment of non-squamous non-small cell lung cancer, can significantly prolong progression-free survival, and overall survival has a trend of benefit
.
Relevant research results suggest that atelizumab combined with chemotherapy has shown more significant efficacy and benefits in Asian populations, and more and more Chinese lung cancer patients will benefit from this immunotherapy
.
(Finish)
Medical Network, June 30, reporters learned on the 29th that the innovative class 1.
1 new drug, Saivotinib, independently developed by Chinese experts for 5 years, was approved by the National Medical Products Administration for the treatment of what was previously known as the "world problem".
Related types of non-small cell lung cancer (NSCLC)
.
1 new drug, Saivotinib, independently developed by Chinese experts for 5 years, was approved by the National Medical Products Administration for the treatment of what was previously known as the "world problem".
Related types of non-small cell lung cancer (NSCLC)
.
It is reported that while "Sivotinib" was approved for listing in China, related clinical studies in many other countries in Europe and America are also in full swing
.
This means that Syvotinib not only fills the gap in this type of targeted drugs in China, but is also expected to become a lung cancer targeted innovative drug that represents China to the world
.
.
This means that Syvotinib not only fills the gap in this type of targeted drugs in China, but is also expected to become a lung cancer targeted innovative drug that represents China to the world
.
Professor Lu Shun, director of the Oncology Department of Shanghai Chest Hospital , told reporters that Saivotinib will bring long-term survival hope to patients with non-small cell lung cancer with skip mutations in MET exon 14
.
According to reports, the MET exon 14 skipping mutation is the driving gene for non-small cell lung cancer (NSCLC).
Patients with this type of lung cancer have rapid disease progression, poor prognosis, and postoperative tumor metastasis
.
Its treatment has always been in dilemma.
In the past, only traditional chemotherapy could be used, but the overall survival time of patients was only 8.
1 months, which is a worldwide problem
.
.
According to reports, the MET exon 14 skipping mutation is the driving gene for non-small cell lung cancer (NSCLC).
Patients with this type of lung cancer have rapid disease progression, poor prognosis, and postoperative tumor metastasis
.
Its treatment has always been in dilemma.
In the past, only traditional chemotherapy could be used, but the overall survival time of patients was only 8.
1 months, which is a worldwide problem
.
Professor Lu Shun introduced in an interview that as early as 2015, he noticed the intractable target of MET
.
November 2016 began, led by Lu Shun China conducted a multi-center clinical trial designed to assess "who Wolfowitz imatinib treatment-related types of non-small cell lung cancer patients with the efficacy and safety"
.
The clinical trial enrolled patients in 32 centers across the country.
The objective response rate was as high as 49.
2%, the progression-free survival period was 6.
8 months, and the longest survival time was more than 4 years
.
.
November 2016 began, led by Lu Shun China conducted a multi-center clinical trial designed to assess "who Wolfowitz imatinib treatment-related types of non-small cell lung cancer patients with the efficacy and safety"
.
The clinical trial enrolled patients in 32 centers across the country.
The objective response rate was as high as 49.
2%, the progression-free survival period was 6.
8 months, and the longest survival time was more than 4 years
.
Mr.
Shen, now 72 years old, is the first patient enrolled in the clinical study
.
In 2017, after Mr.
Shen was diagnosed, the doctor quickly gave him chemotherapy, but the effect was not satisfactory
.
At that time, Lu Shun led the "Sivotinib" related clinical research started.
After Mr.
Shen entered the clinical research, after only taking the medicine for one month, the metastasis was reduced to 2.
4 cm
.
After taking the medicine for more than 3 months, the metastasis was further reduced to 1.
8 cm
.
After taking the medicine for more than four years, the tumor has always maintained this size
.
Now, the old man’s condition is very stable, as long as he comes to the hospital for review regularly
.
Shen, now 72 years old, is the first patient enrolled in the clinical study
.
In 2017, after Mr.
Shen was diagnosed, the doctor quickly gave him chemotherapy, but the effect was not satisfactory
.
At that time, Lu Shun led the "Sivotinib" related clinical research started.
After Mr.
Shen entered the clinical research, after only taking the medicine for one month, the metastasis was reduced to 2.
4 cm
.
After taking the medicine for more than 3 months, the metastasis was further reduced to 1.
8 cm
.
After taking the medicine for more than four years, the tumor has always maintained this size
.
Now, the old man’s condition is very stable, as long as he comes to the hospital for review regularly
.
From a survival period of more than 8 months to more than 4 years now, Professor Lu Shun’s research results on "Sivotinib" have enabled relevant patients to receive more precise treatment and continue their lives
.
The research results were published in the top international academic journal "The Lancet·Respiratory Medicine"
.
.
The research results were published in the top international academic journal "The Lancet·Respiratory Medicine"
.
In an interview with reporters, Professor Lu Shun took the research and development of new lung cancer drugs as an example, and described the history of China's new drug research and development
.
The expert said that from 1999 to 2009, China actively participated in international multi-center clinical research and learned the thinking and methods of clinical trials
.
From 2009 to 2019, Chinese experts not only participated in international multi-center research, but also began to participate in the discussion of experimental plans
.
After 20 years of learning, from 2019 to the present, China's clinical research capabilities have been continuously strengthened, and it has begun to make a "strong tone" in the development of new lung cancer drugs
.
.
The expert said that from 1999 to 2009, China actively participated in international multi-center clinical research and learned the thinking and methods of clinical trials
.
From 2009 to 2019, Chinese experts not only participated in international multi-center research, but also began to participate in the discussion of experimental plans
.
After 20 years of learning, from 2019 to the present, China's clinical research capabilities have been continuously strengthened, and it has begun to make a "strong tone" in the development of new lung cancer drugs
.
It is understood that in recent years, the expert team of Shanghai Chest Hospital has aimed at the research of targeted drugs and immunological drugs for lung cancer, and has actively explored new combined treatment strategies and diagnosis and treatment models
.
From the extremely low 5-year survival rate in the past, lung cancer patients can now live for 10, 15 years or even longer.
Lung cancer has gradually entered the era of "chronic disease"
.
.
From the extremely low 5-year survival rate in the past, lung cancer patients can now live for 10, 15 years or even longer.
Lung cancer has gradually entered the era of "chronic disease"
.
At the same time that Syvotinib was approved, "Tilelizumab combined with chemotherapy for the treatment of non-squamous non-small cell lung cancer" and "Atelizumab combined with chemotherapy for the treatment of non-squamous non-small cell lung cancer" were also approved
.
Professor Lu Shun is the main investigator of these two immunological drugs, bringing treatment options and survival benefits to more types of lung cancer patients
.
The latest research results show that tislelizumab performs well in the first-line treatment of non-squamous non-small cell lung cancer, can significantly prolong progression-free survival, and overall survival has a trend of benefit
.
Relevant research results suggest that atelizumab combined with chemotherapy has shown more significant efficacy and benefits in Asian populations, and more and more Chinese lung cancer patients will benefit from this immunotherapy
.
(Finish)
.
Professor Lu Shun is the main investigator of these two immunological drugs, bringing treatment options and survival benefits to more types of lung cancer patients
.
The latest research results show that tislelizumab performs well in the first-line treatment of non-squamous non-small cell lung cancer, can significantly prolong progression-free survival, and overall survival has a trend of benefit
.
Relevant research results suggest that atelizumab combined with chemotherapy has shown more significant efficacy and benefits in Asian populations, and more and more Chinese lung cancer patients will benefit from this immunotherapy
.
(Finish)
Medical Network, June 30, reporters learned on the 29th that the innovative class 1.
1 new drug, Saivotinib, independently developed by Chinese experts for 5 years, was approved by the National Medical Products Administration for the treatment of what was previously known as the "world problem".
Related types of non-small cell lung cancer (NSCLC)
.
1 new drug, Saivotinib, independently developed by Chinese experts for 5 years, was approved by the National Medical Products Administration for the treatment of what was previously known as the "world problem".
Related types of non-small cell lung cancer (NSCLC)
.
It is reported that while "Sivotinib" was approved for listing in China, related clinical studies in many other countries in Europe and America are also in full swing
.
This means that Syvotinib not only fills the gap in this type of targeted drugs in China, but is also expected to become a lung cancer targeted innovative drug that represents China to the world
.
.
This means that Syvotinib not only fills the gap in this type of targeted drugs in China, but is also expected to become a lung cancer targeted innovative drug that represents China to the world
.
Professor Lu Shun, director of the Oncology Department of Shanghai Chest Hospital , told reporters that Saivotinib will bring long-term survival hope to patients with non-small cell lung cancer with skip mutations in MET exon 14
.
According to reports, the MET exon 14 skipping mutation is the driving gene for non-small cell lung cancer (NSCLC).
Patients with this type of lung cancer have rapid disease progression, poor prognosis, and postoperative tumor metastasis
.
Its treatment has always been in dilemma.
In the past, only traditional chemotherapy could be used, but the overall survival time of patients was only 8.
1 months, which is a worldwide problem
.
Hospital tumor hospital hospital tumor tumor.
According to reports, the MET exon 14 skipping mutation is the driving gene for non-small cell lung cancer (NSCLC).
Patients with this type of lung cancer have rapid disease progression, poor prognosis, and postoperative tumor metastasis
.
Its treatment has always been in dilemma.
In the past, only traditional chemotherapy could be used, but the overall survival time of patients was only 8.
1 months, which is a worldwide problem
.
Professor Lu Shun introduced in an interview that as early as 2015, he noticed the intractable target of MET
.
November 2016 began, led by Lu Shun China conducted a multi-center clinical trial designed to assess "who Wolfowitz imatinib treatment-related types of non-small cell lung cancer patients with the efficacy and safety"
.
The clinical trial enrolled patients in 32 centers across the country.
The objective response rate was as high as 49.
2%, the progression-free survival period was 6.
8 months, and the longest survival time was more than 4 years
.
.
November 2016 began, led by Lu Shun China conducted a multi-center clinical trial designed to assess "who Wolfowitz imatinib treatment-related types of non-small cell lung cancer patients with the efficacy and safety"
.
The clinical trial enrolled patients in 32 centers across the country.
The objective response rate was as high as 49.
2%, the progression-free survival period was 6.
8 months, and the longest survival time was more than 4 years
.
Mr.
Shen, now 72 years old, is the first patient enrolled in the clinical study
.
In 2017, after Mr.
Shen was diagnosed, the doctor quickly gave him chemotherapy, but the effect was not satisfactory
.
At that time, Lu Shun led the "Sivotinib" related clinical research started.
After Mr.
Shen entered the clinical research, after only taking the medicine for one month, the metastasis was reduced to 2.
4 cm
.
After taking the medicine for more than 3 months, the metastasis was further reduced to 1.
8 cm
.
After taking the medicine for more than four years, the tumor has always maintained this size
.
Now, the old man’s condition is very stable, as long as he comes to the hospital for review regularly
.
Shen, now 72 years old, is the first patient enrolled in the clinical study
.
In 2017, after Mr.
Shen was diagnosed, the doctor quickly gave him chemotherapy, but the effect was not satisfactory
.
At that time, Lu Shun led the "Sivotinib" related clinical research started.
After Mr.
Shen entered the clinical research, after only taking the medicine for one month, the metastasis was reduced to 2.
4 cm
.
After taking the medicine for more than 3 months, the metastasis was further reduced to 1.
8 cm
.
After taking the medicine for more than four years, the tumor has always maintained this size
.
Now, the old man’s condition is very stable, as long as he comes to the hospital for review regularly
.
From a survival period of more than 8 months to more than 4 years now, Professor Lu Shun’s research results on "Sivotinib" have enabled relevant patients to receive more precise treatment and continue their lives
.
The research results were published in the top international academic journal "The Lancet·Respiratory Medicine"
.
.
The research results were published in the top international academic journal "The Lancet·Respiratory Medicine"
.
In an interview with reporters, Professor Lu Shun took the research and development of new lung cancer drugs as an example, and described the history of China's new drug research and development
.
The expert said that from 1999 to 2009, China actively participated in international multi-center clinical research and learned the thinking and methods of clinical trials
.
From 2009 to 2019, Chinese experts not only participated in international multi-center research, but also began to participate in the discussion of experimental plans
.
After 20 years of learning, from 2019 to the present, China's clinical research capabilities have been continuously strengthened, and it has begun to make a "strong tone" in the development of new lung cancer drugs
.
.
The expert said that from 1999 to 2009, China actively participated in international multi-center clinical research and learned the thinking and methods of clinical trials
.
From 2009 to 2019, Chinese experts not only participated in international multi-center research, but also began to participate in the discussion of experimental plans
.
After 20 years of learning, from 2019 to the present, China's clinical research capabilities have been continuously strengthened, and it has begun to make a "strong tone" in the development of new lung cancer drugs
.
It is understood that in recent years, the expert team of Shanghai Chest Hospital has aimed at the research of targeted drugs and immunological drugs for lung cancer, and has actively explored new combined treatment strategies and diagnosis and treatment models
.
From the extremely low 5-year survival rate in the past, lung cancer patients can now live for 10, 15 years or even longer.
Lung cancer has gradually entered the era of "chronic disease"
.
.
From the extremely low 5-year survival rate in the past, lung cancer patients can now live for 10, 15 years or even longer.
Lung cancer has gradually entered the era of "chronic disease"
.
At the same time that Syvotinib was approved, "Tilelizumab combined with chemotherapy for the treatment of non-squamous non-small cell lung cancer" and "Atelizumab combined with chemotherapy for the treatment of non-squamous non-small cell lung cancer" were also approved
.
Professor Lu Shun is the main investigator of these two immunological drugs, bringing treatment options and survival benefits to more types of lung cancer patients
.
The latest research results show that tislelizumab performs well in the first-line treatment of non-squamous non-small cell lung cancer, can significantly prolong progression-free survival, and overall survival has a trend of benefit
.
Relevant research results suggest that atelizumab combined with chemotherapy has shown more significant efficacy and benefits in Asian populations, and more and more Chinese lung cancer patients will benefit from this immunotherapy
.
(Finish)
.
Professor Lu Shun is the main investigator of these two immunological drugs, bringing treatment options and survival benefits to more types of lung cancer patients
.
The latest research results show that tislelizumab performs well in the first-line treatment of non-squamous non-small cell lung cancer, can significantly prolong progression-free survival, and overall survival has a trend of benefit
.
Relevant research results suggest that atelizumab combined with chemotherapy has shown more significant efficacy and benefits in Asian populations, and more and more Chinese lung cancer patients will benefit from this immunotherapy
.
(Finish)
